Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival.
New research suggests that an existing blood test may help to determine when someone is likely to develop Alzheimer's disease ...
LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...
CEO and co-founder Brian Sullivan outlined the company’s clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen’s 46th Annual ...
7d
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsMichael Dale - President, CEO & DirectorLindsey Hartley ...
The calls to 911 poured in from staff at Camp East Montana in Texas, the nation’s largest U.S. Immigration and Customs ...
Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results